Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 33 entries
Sorted by: Best Match Show Resources per page
Loss of Metabolic Flexibility in the Failing Heart.

Frontiers in cardiovascular medicine

Karwi QG, Uddin GM, Ho KL, Lopaschuk GD.
PMID: 29928647
Front Cardiovasc Med. 2018 Jun 06;5:68. doi: 10.3389/fcvm.2018.00068. eCollection 2018.

To maintain its high energy demand the heart is equipped with a highly complex and efficient enzymatic machinery that orchestrates ATP production using multiple energy substrates, namely fatty acids, carbohydrates (glucose and lactate), ketones and amino acids. The contribution...

Cite
Karwi QG, Uddin GM, Ho KL, et al. Loss of Metabolic Flexibility in the Failing Heart. Front Cardiovasc Med. 2018;5:68doi: 10.3389/fcvm.2018.00068.
Karwi, Q. G., Uddin, G. M., Ho, K. L., & Lopaschuk, G. D. (2018). Loss of Metabolic Flexibility in the Failing Heart. Frontiers in cardiovascular medicine, 568. https://doi.org/10.3389/fcvm.2018.00068
Karwi, Qutuba G, et al. "Loss of Metabolic Flexibility in the Failing Heart." Frontiers in cardiovascular medicine vol. 5 (2018): 68. doi: https://doi.org/10.3389/fcvm.2018.00068
Karwi QG, Uddin GM, Ho KL, Lopaschuk GD. Loss of Metabolic Flexibility in the Failing Heart. Front Cardiovasc Med. 2018 Jun 06;5:68. doi: 10.3389/fcvm.2018.00068. eCollection 2018. PMID: 29928647; PMCID: PMC5997788.
Copy Download .nbib Format: NLM
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.

JACC. Basic to translational science

Lopaschuk GD, Verma S.
PMID: 32613148
JACC Basic Transl Sci. 2020 Jun 22;5(6):632-644. doi: 10.1016/j.jacbts.2020.02.004. eCollection 2020 Jun.

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of cardiovascular death and heart failure hospitalization in people with and without diabetes, and those with and...

Cite
Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632-644doi: 10.1016/j.jacbts.2020.02.004.
Lopaschuk, G. D., & Verma, S. (2020). Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC. Basic to translational science, 5(6), 632-644. https://doi.org/10.1016/j.jacbts.2020.02.004
Lopaschuk, Gary D, and Verma, Subodh. "Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review." JACC. Basic to translational science vol. 5,6 (2020): 632-644. doi: https://doi.org/10.1016/j.jacbts.2020.02.004
Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020 Jun 22;5(6):632-644. doi: 10.1016/j.jacbts.2020.02.004. eCollection 2020 Jun. PMID: 32613148; PMCID: PMC7315190.
Copy Download .nbib Format: NLM
Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart.

Metabolism: clinical and experimental

Uddin GM, Karwi QG, Pherwani S, Gopal K, Wagg CS, Biswas D, Atnasious M, Wu Y, Wu G, Zhang L, Ho KL, Pulinilkunnil T, Ussher JR, Lopaschuk GD.
PMID: 34478752
Metabolism. 2021 Nov;124:154871. doi: 10.1016/j.metabol.2021.154871. Epub 2021 Sep 01.

BACKGROUNDS: Branched chain amino acid (BCAA) oxidation is impaired in cardiac insulin resistance, leading to the accumulation of BCAAs and the first products of BCAA oxidation, the branched chain ketoacids. However, it is not clear whether it is the...

Cite
Uddin GM, Karwi QG, Pherwani S, et al. Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart. Metabolism. 2021;124:154871doi: 10.1016/j.metabol.2021.154871.
Uddin, G. M., Karwi, Q. G., Pherwani, S., Gopal, K., Wagg, C. S., Biswas, D., Atnasious, M., Wu, Y., Wu, G., Zhang, L., Ho, K. L., Pulinilkunnil, T., Ussher, J. R., & Lopaschuk, G. D. (2021). Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart. Metabolism: clinical and experimental, 124154871. https://doi.org/10.1016/j.metabol.2021.154871
Uddin, Golam M, et al. "Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart." Metabolism: clinical and experimental vol. 124 (2021): 154871. doi: https://doi.org/10.1016/j.metabol.2021.154871
Uddin GM, Karwi QG, Pherwani S, Gopal K, Wagg CS, Biswas D, Atnasious M, Wu Y, Wu G, Zhang L, Ho KL, Pulinilkunnil T, Ussher JR, Lopaschuk GD. Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart. Metabolism. 2021 Nov;124:154871. doi: 10.1016/j.metabol.2021.154871. Epub 2021 Sep 01. PMID: 34478752.
Copy Download .nbib Format: NLM
Targeting the Brain to Protect the Heart.

JACC. Basic to translational science

Lopaschuk GD.
PMID: 33533757
JACC Basic Transl Sci. 2021 Jan 25;6(1):71-73. doi: 10.1016/j.jacbts.2020.12.004. eCollection 2021 Jan.

No abstract available.

Cite
Lopaschuk GD. Targeting the Brain to Protect the Heart. JACC Basic Transl Sci. 2021;6(1):71-73doi: 10.1016/j.jacbts.2020.12.004.
Lopaschuk, G. D. (2021). Targeting the Brain to Protect the Heart. JACC. Basic to translational science, 6(1), 71-73. https://doi.org/10.1016/j.jacbts.2020.12.004
Lopaschuk, Gary D. "Targeting the Brain to Protect the Heart." JACC. Basic to translational science vol. 6,1 (2021): 71-73. doi: https://doi.org/10.1016/j.jacbts.2020.12.004
Lopaschuk GD. Targeting the Brain to Protect the Heart. JACC Basic Transl Sci. 2021 Jan 25;6(1):71-73. doi: 10.1016/j.jacbts.2020.12.004. eCollection 2021 Jan. PMID: 33533757; PMCID: PMC7838095.
Copy Download .nbib Format: NLM
Metabolic, structural and biochemical changes in diabetes and the development of heart failure.

Diabetologia

Ho KL, Karwi QG, Connolly D, Pherwani S, Ketema EB, Ussher JR, Lopaschuk GD.
PMID: 34994805
Diabetologia. 2022 Jan 07; doi: 10.1007/s00125-021-05637-7. Epub 2022 Jan 07.

Diabetes contributes to the development of heart failure through various metabolic, structural and biochemical changes. The presence of diabetes increases the risk for the development of cardiovascular disease (CVD), and since the introduction of cardiovascular outcome trials to test...

Cite
Ho KL, Karwi QG, Connolly D, et al. Metabolic, structural and biochemical changes in diabetes and the development of heart failure. Diabetologia. 2022;doi: 10.1007/s00125-021-05637-7.
Ho, K. L., Karwi, Q. G., Connolly, D., Pherwani, S., Ketema, E. B., Ussher, J. R., & Lopaschuk, G. D. (2022). Metabolic, structural and biochemical changes in diabetes and the development of heart failure. Diabetologia, . https://doi.org/10.1007/s00125-021-05637-7
Ho, Kim L, et al. "Metabolic, structural and biochemical changes in diabetes and the development of heart failure." Diabetologia vol. (2022). doi: https://doi.org/10.1007/s00125-021-05637-7
Ho KL, Karwi QG, Connolly D, Pherwani S, Ketema EB, Ussher JR, Lopaschuk GD. Metabolic, structural and biochemical changes in diabetes and the development of heart failure. Diabetologia. 2022 Jan 07; doi: 10.1007/s00125-021-05637-7. Epub 2022 Jan 07. PMID: 34994805.
Copy Download .nbib Format: NLM
Review of the top 5 cardiology studies of 2019-20.

Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC

Barry AR, Babadagli HE, Boswell R, Chen JW, Dawson EL, Lopaschuk DG, McMillan CL, Nguyen BV, Omar MA, Pollmann DM, Zhou JS, Ackman ML.
PMID: 34777649
Can Pharm J (Ott). 2021 Jul 14;154(6):388-393. doi: 10.1177/17151635211029328. eCollection 2021.

No abstract available.

Cite
Barry AR, Babadagli HE, Boswell R, et al. Review of the top 5 cardiology studies of 2019-20. Can Pharm J (Ott). 2021;154(6):388-393doi: 10.1177/17151635211029328.
Barry, A. R., Babadagli, H. E., Boswell, R., Chen, J. W., Dawson, E. L., Lopaschuk, D. G., McMillan, C. L., Nguyen, B. V., Omar, M. A., Pollmann, D. M., Zhou, J. S., & Ackman, M. L. (2021). Review of the top 5 cardiology studies of 2019-20. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC, 154(6), 388-393. https://doi.org/10.1177/17151635211029328
Barry, Arden R, et al. "Review of the top 5 cardiology studies of 2019-20." Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC vol. 154,6 (2021): 388-393. doi: https://doi.org/10.1177/17151635211029328
Barry AR, Babadagli HE, Boswell R, Chen JW, Dawson EL, Lopaschuk DG, McMillan CL, Nguyen BV, Omar MA, Pollmann DM, Zhou JS, Ackman ML. Review of the top 5 cardiology studies of 2019-20. Can Pharm J (Ott). 2021 Jul 14;154(6):388-393. doi: 10.1177/17151635211029328. eCollection 2021. PMID: 34777649; PMCID: PMC8581808.
Copy Download .nbib Format: NLM
Ablation of Akt2 and AMPK.

Acta pharmaceutica Sinica. B

Wang S, Tao J, Chen H, Kandadi MR, Sun M, Xu H, Lopaschuk GD, Lu Y, Zheng J, Peng H, Ren J.
PMID: 34900533
Acta Pharm Sin B. 2021 Nov;11(11):3508-3526. doi: 10.1016/j.apsb.2021.07.006. Epub 2021 Jul 14.

Given the opposing effects of Akt and AMP-activated protein kinase (AMPK) on metabolic homeostasis, this study examined the effects of deletion of Akt2 and AMPK

Cite
Wang S, Tao J, Chen H, et al. Ablation of Akt2 and AMPK. Acta Pharm Sin B. 2021;11(11):3508-3526doi: 10.1016/j.apsb.2021.07.006.
Wang, S., Tao, J., Chen, H., Kandadi, M. R., Sun, M., Xu, H., Lopaschuk, G. D., Lu, Y., Zheng, J., Peng, H., & Ren, J. (2021). Ablation of Akt2 and AMPK. Acta pharmaceutica Sinica. B, 11(11), 3508-3526. https://doi.org/10.1016/j.apsb.2021.07.006
Wang, Shuyi, et al. "Ablation of Akt2 and AMPK." Acta pharmaceutica Sinica. B vol. 11,11 (2021): 3508-3526. doi: https://doi.org/10.1016/j.apsb.2021.07.006
Wang S, Tao J, Chen H, Kandadi MR, Sun M, Xu H, Lopaschuk GD, Lu Y, Zheng J, Peng H, Ren J. Ablation of Akt2 and AMPK. Acta Pharm Sin B. 2021 Nov;11(11):3508-3526. doi: 10.1016/j.apsb.2021.07.006. Epub 2021 Jul 14. PMID: 34900533; PMCID: PMC8642450.
Copy Download .nbib Format: NLM
Novel O-palmitolylated beta-E1 subunit of pyruvate dehydrogenase is phosphorylated during ischemia/reperfusion injury.

Proteome science

Folmes CD, Sawicki G, Cadete VJ, Masson G, Barr AJ, Lopaschuk GD.
PMID: 20618950
Proteome Sci. 2010 Jul 09;8:38. doi: 10.1186/1477-5956-8-38.

BACKGROUND: During and following myocardial ischemia, glucose oxidation rates are low and fatty acids dominate as a source of oxidative metabolism. This metabolic phenotype is associated with contractile dysfunction during reperfusion. To determine the mechanism of this reliance on...

Cite
Folmes CD, Sawicki G, Cadete VJ, et al. Novel O-palmitolylated beta-E1 subunit of pyruvate dehydrogenase is phosphorylated during ischemia/reperfusion injury. Proteome Sci. 2010;8:38doi: 10.1186/1477-5956-8-38.
Folmes, C. D., Sawicki, G., Cadete, V. J., Masson, G., Barr, A. J., & Lopaschuk, G. D. (2010). Novel O-palmitolylated beta-E1 subunit of pyruvate dehydrogenase is phosphorylated during ischemia/reperfusion injury. Proteome science, 838. https://doi.org/10.1186/1477-5956-8-38
Folmes, Clifford Dl, et al. "Novel O-palmitolylated beta-E1 subunit of pyruvate dehydrogenase is phosphorylated during ischemia/reperfusion injury." Proteome science vol. 8 (2010): 38. doi: https://doi.org/10.1186/1477-5956-8-38
Folmes CD, Sawicki G, Cadete VJ, Masson G, Barr AJ, Lopaschuk GD. Novel O-palmitolylated beta-E1 subunit of pyruvate dehydrogenase is phosphorylated during ischemia/reperfusion injury. Proteome Sci. 2010 Jul 09;8:38. doi: 10.1186/1477-5956-8-38. PMID: 20618950; PMCID: PMC2909933.
Copy Download .nbib Format: NLM
Post-translational Acetylation Control of Cardiac Energy Metabolism.

Frontiers in cardiovascular medicine

Ketema EB, Lopaschuk GD.
PMID: 34409084
Front Cardiovasc Med. 2021 Aug 02;8:723996. doi: 10.3389/fcvm.2021.723996. eCollection 2021.

Perturbations in myocardial energy substrate metabolism are key contributors to the pathogenesis of heart diseases. However, the underlying causes of these metabolic alterations remain poorly understood. Recently, post-translational acetylation-mediated modification of metabolic enzymes has emerged as one of the...

Cite
Ketema EB, Lopaschuk GD. Post-translational Acetylation Control of Cardiac Energy Metabolism. Front Cardiovasc Med. 2021;8:723996doi: 10.3389/fcvm.2021.723996.
Ketema, E. B., & Lopaschuk, G. D. (2021). Post-translational Acetylation Control of Cardiac Energy Metabolism. Frontiers in cardiovascular medicine, 8723996. https://doi.org/10.3389/fcvm.2021.723996
Ketema, Ezra B, and Lopaschuk, Gary D. "Post-translational Acetylation Control of Cardiac Energy Metabolism." Frontiers in cardiovascular medicine vol. 8 (2021): 723996. doi: https://doi.org/10.3389/fcvm.2021.723996
Ketema EB, Lopaschuk GD. Post-translational Acetylation Control of Cardiac Energy Metabolism. Front Cardiovasc Med. 2021 Aug 02;8:723996. doi: 10.3389/fcvm.2021.723996. eCollection 2021. PMID: 34409084; PMCID: PMC8365027.
Copy Download .nbib Format: NLM
Inhibition of lipid metabolism exerts antitumor effects on rhabdomyosarcoma.

Cancer medicine

Miyagaki S, Kikuchi K, Mori J, Lopaschuk GD, Iehara T, Hosoi H.
PMID: 34472721
Cancer Med. 2021 Sep;10(18):6442-6455. doi: 10.1002/cam4.4185. Epub 2021 Sep 02.

Rhabdomyosarcoma exhibits tumor-specific energy metabolic changes that include the Warburg effect. Since targeting cancer metabolism is a promising therapeutic approach, we examined the antitumor effects of suppressing lipid metabolism in rhabdomyosarcoma. We suppressed lipid metabolism in rhabdomyosarcoma cells in...

Cite
Miyagaki S, Kikuchi K, Mori J, et al. Inhibition of lipid metabolism exerts antitumor effects on rhabdomyosarcoma. Cancer Med. 2021;10(18):6442-6455doi: 10.1002/cam4.4185.
Miyagaki, S., Kikuchi, K., Mori, J., Lopaschuk, G. D., Iehara, T., & Hosoi, H. (2021). Inhibition of lipid metabolism exerts antitumor effects on rhabdomyosarcoma. Cancer medicine, 10(18), 6442-6455. https://doi.org/10.1002/cam4.4185
Miyagaki, Satoshi, et al. "Inhibition of lipid metabolism exerts antitumor effects on rhabdomyosarcoma." Cancer medicine vol. 10,18 (2021): 6442-6455. doi: https://doi.org/10.1002/cam4.4185
Miyagaki S, Kikuchi K, Mori J, Lopaschuk GD, Iehara T, Hosoi H. Inhibition of lipid metabolism exerts antitumor effects on rhabdomyosarcoma. Cancer Med. 2021 Sep;10(18):6442-6455. doi: 10.1002/cam4.4185. Epub 2021 Sep 02. PMID: 34472721; PMCID: PMC8446407.
Copy Download .nbib Format: NLM
Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart.

Metabolism: clinical and experimental

Uddin GM, Karwi QG, Pherwani S, Gopal K, Wagg CS, Biswas D, Atnasious M, Wu Y, Wu G, Zhang L, Ho KL, Pulinilkunnil T, Ussher JR, Lopaschuk GD.
PMID: 34478752
Metabolism. 2021 Nov;124:154871. doi: 10.1016/j.metabol.2021.154871. Epub 2021 Sep 01.

BACKGROUNDS: Branched chain amino acid (BCAA) oxidation is impaired in cardiac insulin resistance, leading to the accumulation of BCAAs and the first products of BCAA oxidation, the branched chain ketoacids. However, it is not clear whether it is the...

Cite
Uddin GM, Karwi QG, Pherwani S, et al. Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart. Metabolism. 2021;124:154871doi: 10.1016/j.metabol.2021.154871.
Uddin, G. M., Karwi, Q. G., Pherwani, S., Gopal, K., Wagg, C. S., Biswas, D., Atnasious, M., Wu, Y., Wu, G., Zhang, L., Ho, K. L., Pulinilkunnil, T., Ussher, J. R., & Lopaschuk, G. D. (2021). Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart. Metabolism: clinical and experimental, 124154871. https://doi.org/10.1016/j.metabol.2021.154871
Uddin, Golam M, et al. "Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart." Metabolism: clinical and experimental vol. 124 (2021): 154871. doi: https://doi.org/10.1016/j.metabol.2021.154871
Uddin GM, Karwi QG, Pherwani S, Gopal K, Wagg CS, Biswas D, Atnasious M, Wu Y, Wu G, Zhang L, Ho KL, Pulinilkunnil T, Ussher JR, Lopaschuk GD. Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart. Metabolism. 2021 Nov;124:154871. doi: 10.1016/j.metabol.2021.154871. Epub 2021 Sep 01. PMID: 34478752.
Copy Download .nbib Format: NLM
Corrigendum to "Trimetazidine in cardiovascular medicine," [Int. J. Cardiol., 293 (2019) 39-44].

International journal of cardiology

Marzilli M, Vinereanu D, Lopaschuk G, Chen Y, Dalal JJ, Danchin N, Etriby E, Ferrari R, Gowdak LH, Lopatin Y, Milicic D, Parkhomenko A, Pinto F, Ponikowski P, Seferovic P, Rosano GMC.
PMID: 32891464
Int J Cardiol. 2020 Dec 01;320:26. doi: 10.1016/j.ijcard.2020.06.027. Epub 2020 Sep 03.

No abstract available.

Cite
Marzilli M, Vinereanu D, Lopaschuk G, et al. Corrigendum to "Trimetazidine in cardiovascular medicine," [Int. J. Cardiol., 293 (2019) 39-44]. Int J Cardiol. 2020;320:26doi: 10.1016/j.ijcard.2020.06.027.
Marzilli, M., Vinereanu, D., Lopaschuk, G., Chen, Y., Dalal, J. J., Danchin, N., Etriby, E., Ferrari, R., Gowdak, L. H., Lopatin, Y., Milicic, D., Parkhomenko, A., Pinto, F., Ponikowski, P., Seferovic, P., & Rosano, G. M. C. (2020). Corrigendum to "Trimetazidine in cardiovascular medicine," [Int. J. Cardiol., 293 (2019) 39-44]. International journal of cardiology, 32026. https://doi.org/10.1016/j.ijcard.2020.06.027
Marzilli, Mario, et al. "Corrigendum to "Trimetazidine in cardiovascular medicine," [Int. J. Cardiol., 293 (2019) 39-44]." International journal of cardiology vol. 320 (2020): 26. doi: https://doi.org/10.1016/j.ijcard.2020.06.027
Marzilli M, Vinereanu D, Lopaschuk G, Chen Y, Dalal JJ, Danchin N, Etriby E, Ferrari R, Gowdak LH, Lopatin Y, Milicic D, Parkhomenko A, Pinto F, Ponikowski P, Seferovic P, Rosano GMC. Corrigendum to "Trimetazidine in cardiovascular medicine," [Int. J. Cardiol., 293 (2019) 39-44]. Int J Cardiol. 2020 Dec 01;320:26. doi: 10.1016/j.ijcard.2020.06.027. Epub 2020 Sep 03. PMID: 32891464.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 33 entries